Novartis Patient Support
A dedicated team for you and your patients
Novartis Patient Support is a comprehensive program that can help your patients start and stay on treatment.
Novartis Patient Support is a comprehensive program that can help your patients start and stay on treatment.
The Novartis Patient Support Co-Pay Plus program is available to patients with commercial or private insurance (that is, insurance provided by an employer or purchased individually) who meet specific eligibility criteria. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, eg, co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payers of any benefits they receive and the value of this program, as required by contract or otherwise. This program is void where prohibited by law or restricted. Novartis Patient Support is not an insurance program and is not a substitute for medical insurance. Eligibility restrictions may apply.
Risk From Radiation Exposure
PLUVICTO contributes to a patient’s long-term cumulative radiation exposure, which is associated with an increased risk for cancer.
Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with PLUVICTO consistent with institutional practices, patient treatment procedures, Nuclear...
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy...